Floatz logo

Anvumetostat

MTAP-null Solid Tumors

AmgenSmall moleculePhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the MTAP-null Solid Tumors cohort.

Asset / SponsorPhaseRating
MAT2A-IN-9
Amgen
Phase 1/2CCC

Same molecule, other indications

Anvumetostat is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
Advanced MTAP-null Solid TumorsDormant
CCC
Indicative ·
48 / 100
View asset →
digestive system cancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →